Ratings PolyPeptide Group AG

Equities

PPGN

CH1110760852

Real-time Estimate Cboe Europe Other stock markets 05:15:09 2024-05-15 am EDT			5-day change	1st Jan Change
33.88 ^CHF	+2.34%		+9.89%	+93.49%

Mar. 12	PolyPeptide Group AG Provides Earnings Guidance for 2024	CI
Mar. 12	Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

Low profitability weakens the company.
The company's enterprise value to sales, at 3.33 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
POLYPEPTIDE GROUP AG	+93.49%	1.2B	B-
NOVO NORDISK A/S	+31.81%	588B	B
JOHNSON & JOHNSON	-3.42%	364B	C+
MERCK & CO., INC.	+18.02%	326B	B-
ABBVIE INC.	+4.27%	285B	C+
ASTRAZENECA PLC	+15.23%	239B	B+
NOVARTIS AG	+9.93%	210B	B-
ROCHE HOLDING AG	-7.20%	200B	A+
AMGEN INC.	+8.12%	167B	C+
PFIZER, INC.	-1.42%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes